Jump to content

Dean Pomerleau

Lifetime Member
  • Content Count

  • Joined

  • Last visited

About Dean Pomerleau

  • Birthday 11/12/1964

Profile Information

  • Gender

Recent Profile Visitors

6,109 profile views
  1. Dean Pomerleau

    LDL: What's Optimal For Health And Longevity?

    Neither of us consume oils, extra virgin or otherwise. --Dean
  2. Dean Pomerleau

    Healthiest Greens?

    Sounds like an improvement! The more variety you can work in the better. --Dean
  3. Maybe that's because too much of your diet consists of highly-processed, pig-fat-laden Purina monkey chow with too much protein and added methionine. I know you also eat a lot of veggies, but maybe your blood work would improve without the need for such severe CR if you ditched the monkey chow and started eating a wider variety of healthy whole plant foods like legumes, nuts, seeds, avocados, fruits and whole grains. -Dean
  4. Compared with what? Definitely more than a few years compared to the standard western diet and lifestyle, as shown by the Wisconsin monkey trial. But very likely only a few years (if that) when compared to a healthy obesity-avoiding diet and lifestyle like practiced by the Adventists, as illustrated by the NIA monkey trial. --Dean
  5. It isn't "mainstream science" that questions the efficacy of CR in humans, it is the scientific evidence that has piled up since Roy's untimely death (discussed at length here), including the disappointing results of the CR monkey trials and the inconsistency of CR benefits even in rodents of different strains (including non-f*cked up wild-type mice) that has undermined the idea that CR is will dramatically extend human longevity. [On related side note - do you find it ironic that the only good evidence for CR longevity benefits come from studies of lab mice, which your buddy and fellow iconoclast Bret Weinstein calls "genetic freaks" and who likes to blather on about how bad they are as a model for human disease and aging? Because mainstream science has heavily relied on evidence from studies of messed up lab mice, the one thing Bret agrees with Aubrey de Grey on is that CR won't significantly extend human lifespan (pdf) ] Roy was a true scientist. I like to think he would have come to the same conclusion as other longevity researchers when the evidence became clear that lifelong severe CR will at best add a few years to human lifespan relative to a healthy, obesity-avoiding diet and lifestyle (e.g. that of the mostly-vegetarian, normal-weight Adventists) and distanced himself from the hype he wrote in Beyond the 120-Year Diet shortly before he died, like: "... [T]he CRON diet will retard your rate of aging and extend lifespan (up to perhaps 150 to 160 years depending on when you start and how thoroughly you hold to it)... It does Roy's memory and his body of work a serious disservice to make an analogy between him and the cadre of conspiracy theorists, discredited MDs and "health coaches" who promote the ideas and treatments you've been sharing lately. I think his daughter Lisa would feel the same way. I was heartened to see from her blog that she is following the science - her newly-reopened yoga center requires both masks and proof of vaccination for all participants. Her co-author on The Longevity Diet, Roy's friend and founding member and President(?) of the CR Society, Brian Delaney is also following the science. He admits at 16:00 of this 2019 video that Roy's extremely bold predictions about the benefits of CR for humans were "almost certainly a mistake" (citing the studies of CR in non-human primates) but modestly and honestly says the evidence suggests "[CR] will almost certainly slow aging at least a bit." Lately he's been working on covid challenge trials and open source vaccines. --Dean
  6. Dean Pomerleau

    Eating Natto for Bone, Artery & Brain Health

    Here is a new, relatively-large, well-designed, three-year randomized control trial of nattokinase supplements for cardiovascular health in healthy older people at low risk of CVD [1]. It basically found nattokinase to be ineffective. Here are the main tables from the paper, showing nattokinase (2000 FU/day) had no significant impact on a wide range of measures of cardiovascular health, including arterial thickness or stiffness, cholesterol, glucose, insulin, blood pressure, or various measurements of blood coagulation tendency: So if you are taking a nattokinase supplement for its potential to improve cardiovascular health, it looks like it probably isn't worth it. One concern we previously discussed was the potential for nattokinase to act as a blood thinner which might be bad for CR folks with already thin blood, which could trigger bleeding/stroke. That doesn't look like a problem. The author's acknowledged that the cohort was healthier and the dose was lower than previous studies which hinted at potential benefits of nattokinase for cardiovascular health. But the demographics and dosage of this study seems quite relevant for folks here. The authors also said natto contains other active compounds besides nattokinase, but the thought has been that it would be the nattokinase (if anything) in natto that would positively influence CVD due to its pharmokinetics and animal experiments. The study doesn't address the two other potential benefits of eat natto, i.e. brain health (for its potential to break up amyloid plaques) and bone health (from its high level of vitamin K2). --Dean ------ [1] Clinical Hemorheology and Microcirculation, vol. Pre-press, no. Pre-press, pp. 1-15, 2021 Nattokinase Atherothrombotic Prevention Study: A randomized controlled trial Authors: Hodis, Howard N.a; b; c; * | Mack, Wendy J.a; c | Meiselman, Herbert J.d | Kalra, Vijaye | Liebman, Howardb | Hwang-Levine, Julianaa; b | Dustin, Lauriec | Kono, Naokoc | Mert, Melissac | Wenby, Rosalinda B.d | Huesca, Emilianoe | Rochanda, Leanneb | Li, Yanjiea | Yan, Mingzhua | St. John, Jan Aa; c | Whitfield, Loraa Abstract: BACKGROUND:Described to be antithrombotic and antihypertensive, nattokinase is consumed for putative cardiovascular benefit. However, no large-scale, long-term cardiovascular study has been conducted with nattokinase supplementation. OBJECTIVE:To determine the effect of nattokinase on subclinical atherosclerosis progression and atherothrombotic biomarkers. METHODS:In this double-blinded trial, 265 individuals of median age 65.3 years, without clinical evidence of cardiovascular disease (CVD) were randomized to oral nattokinase 2,000 fibrinolytic units or matching placebo. Primary outcome was rate of change in subclinical atherosclerosis measured by serial carotid ultrasound every 6 months as carotid artery intima-media thickness (CIMT) and carotid arterial stiffness (CAS). Additional outcomes determined at least every 6 months were clinical parameters including blood pressure and laboratory measures including metabolic factors, blood rheology parameters, blood coagulation and fibrinolysis factors, inflammatory markers and monocyte/macrophage cellular activation markers. RESULTS:After median 3 years of randomized treatment, annualized rate of change in CIMT and CAS did not significantly differ between nattokinase supplementation and placebo. Additionally, there was no significant effect of nattokinase supplementation on blood pressure or any laboratory determination. CONCLUSIONS:Results of this trial show that nattokinase supplementation has a null effect on subclinical atherosclerosis progression in healthy individuals at low risk for CVD. DOI: 10.3233/CH-211147
  7. Dean Pomerleau

    Michael Rae on Hyberbaric Oxygen Treatment Study

    From the Sept 8th SENS Research Newsletter : Hyperbolic Hyperbaric "Age Reversal" A recent publication in the journal Aging claimed to show "increased telomere length and decreases in immunosenescence" (with supposed implications for overall health and aging) in response to hyperbaric oxygen therapy (HBOT). As exciting as that may sound on the surface, close examination of the study design reveals numerous flaws. Hype doesn't help advance the progress of genuinely promising rejuvenation biotechnologies, and here at SRF, we are committed not only to pushing for more science in the aging-damage-repair realm, but to promoting better science and avoiding the pitfalls of poor study design. Read a full breakdown of the HBOT study by SRF science writer Michael Rae on our website. --Dean
  8. Here is an useful visualization from Axios illustrating the point that Todd made last week, namely that the virus is continuing to rapidly mutate. It shows the prevalence of different variants in the US over the course of the year: It shows the Alpha variant being rapidly replaced by Delta in June, and the original Delta strain slowly getting superceded by several different Delta substrains over the past couple months. --Dean
  9. Dean Pomerleau

    LDL: What's Optimal For Health And Longevity?

    Amla Experiment Results Results from my wife's 90-day experiment with taking an Amla supplement for her moderately high cholesterol are in. She religiously took two capsules per day (morning and evening) and didn't change her quite-healthy, near-vegan diet or exercise pattern. Here are her LDL and HDL levels for the last few years, with the last two from May 2021 (pre-amla) and yesterday (post-amla) : LDL: 130, 133, 133, 126, 116 HDL: 067, 076, 071, 071, 074 Overall we were pleasantly surprised. An apparent drop in LDL of 10-15 mg/dL compared with where it has been consistently for the last few years, along with perhaps a slight increase in HDL after taking an inexpensive amla supplement for three months seems pretty good. Her LDL is still on the high side, but we've decided to continue with the amla rather than considering a statin for now. We'll reevaluate her cholesterol level in a year. --Dean
  10. No of course not. But returning to widespread masking (on top of vaccines) might help prevent our hospitals from being overwhelmed and having to institute business closures, on-line schooling and lockdowns again. --Dean
  11. Gordo, I totally understand feeling covid fatigue at this point in the pandemic, especially after losing a friend to the disease. You may be right and vitually everyone is destined to get covid eventually so why take extra, inconvenient steps like masking to avoid it. All I can offer is an analog with aging and death. Despite what some folks in the anti-aging community like to believe, we are all going to get old and die eventually. Maybe our grand kids won't, but we will. But that doesn't mean that I stop doing what I can to remain healthy and postpone death, even at some near term cost in convenience and hedonistic enjoyment. We all have to decide for ourselves how we want to balance risk vs annoyance. Just like with CR, many will fall off the wagon. And just like with the 1918 flu, a couple years down the road there will be some people who can look back and say I was careful and didn't get covid during its more deadly waves. I'm someone who is willing to endure interventions than many people seem to consider too burdensome at this point In order to increase my chances of being one of them. And if I do end up getting covid, interventions like masking (and obviously vaccination!) should help to minimize its severity and its long-term impact on my health. YMMV. --Dean
  12. Large Study Confirms Masks Work to Limit COVID-19 Spread The mask intervention was tested in a randomized control trial in Bangladesh on 350,000 people in many different villages. The intervention resulted in a 28% increase in people wearing masks (13% -> 42%) which in turn resulted in a 10% decrease in confirmed symptomatic cases of covid. If you naively linearly scaled that result so that it was going from 0% mass usage to 100% mask usage, it would equate to a 36% reduction in symptomatic covid infections. That is likely a substantial underestimate for reasons given in article, and because the benefits of nearly universal mask usage would almost certainly be super-linear, since near universal masking would greatly increase the fraction of encounters between masked infected people and masked uninfected people, which are the type of encounter where masks are most effective. --Dean
  13. For those of you who, like me, miss Michael Rae's insightful contributions to this forum, here is a review from him of a (pretty bad) study of hyperbaric oxygen therapy that makes some bold and unsubstantiated claims about reversing aging. https://www.sens.org/hyperbolic-hyperbaric-age-reversal/ --Dean
  14. Results from the Together trial, the largest to-date randomized control trial of ivermectin for treatment of covid have been announced (via video - not yet published). They randomly assigned 1350 people in Brazil across ten clinics who just been diagnosed with Covid to receive either three days treatment of ivermectin or placebo. The outcomes they looked at were ER visits due to worsening symptoms, hospitalizations and mortailty. They found ivermectin provided no benefit relative to placebo, with 86 ER visits/hospitalizations in the ivermectin group vs. 95 in the placebo group, which was not a statistical significant different (CI 0.69 - 1.19). Impact on mortality risk was also non-significant (CI 0.44 - 1.52). This is the second time the Together trial has tested ivermectin, this time with a higher dose and longer treatment, and again it failed to show any benefit. The researchers report they have dropped the ivermectin protocol from their trial in order to focus on more promising treatments with different repurposed drugs. Hydroxychloroquine and metformin were also found previously to be ineffective by this same group. Below is the slide the researchers shared about the ivermectin results at around 31 minutes of the video. --Dean
  15. From this article in The Atlantic: What We Actually Know About Waning Immunity. Some reports from Israel appear to paint a more dire portrait: A few preliminary numbers released by the country’s Ministry of Health suggested that vaccine effectiveness against both infection and symptomatic disease had dipped to about 40 percent. But Çevik, of the University of St. Andrews, told me that these and other data reporting heftier declines are messy and might actually overestimate the problem. Across countries, early vaccine recipients tended to be older, in slightly worse health, and in higher-risk professions than those who got injected later on. That alone could make the protection that they got seem less impressive in comparison. Also, when initial effectiveness numbers were calculated, people were adhering more to physical distancing and masks. Measured these days, amid more lax behavior, risk of infection would rise. And as more of the unvaccinated have been infected, their collective immunity has grown, making them, too, less susceptible to the virus—which could make the effectiveness of vaccines look lower. ... When it comes to severe disease and death, though, vaccine effectiveness hasn’t really budged at all: Immunized people seem to be thwarting the worst cases of COVID-19 just as well as they did when the shots debuted, often at rates well into the 90s. That’s fantastic, considering that the FDA’s original benchmark for vaccine success, announced in June 2020, was reducing the risk of disease or serious disease by 50 percent among people who get the shot. So far, there is simply no “evidence of a substantial decline” against the worst outcomes, Saad Omer, an epidemiologist at Yale, told me. ... For the rest of us, though, the perks [of a booster shot] are harder to visualize. In someone with a fully functional immune system whose defenses were already substantially shored up by their first shots, more doses would probably increase antibody production. That, in turn, could further cut down on infection and transmission, Gommerman told me. Very early data hint that this may be happening in Israel, which is already boosting widely. But it’s not clear how long that preventive bump would last. Ellebedy, of Washington University in St. Louis, said boosters would have “real gain” only if they expanded on the body’s capacity to manufacture antibodies long term, instead of just fueling a temporary boom-and-bust. It’s especially unclear whether that would happen with yet another injection of the original vaccine recipe, delivered to the arm—as opposed to, say, a nasal spray with Delta-specific ingredients. --Dean